Last reviewed · How we verify

Genmab — Portfolio Competitive Intelligence Brief

Genmab (GMAB) pipeline: 0 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

GMAB (NASDAQ) 0 marketed 0 filed 2 Phase 3 2 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Investigator's Choice Chemotherapy Investigator's Choice Chemotherapy phase 3 Oncology
Rina-S Rina-S phase 3 Bispecific antibody Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Allakos Inc. · 1 shared drug class
  2. Allergan · 1 shared drug class
  3. Amgen · 1 shared drug class
  4. AstraZeneca · 1 shared drug class
  5. Atom Therapeutics Co., Ltd · 1 shared drug class
  6. BioNTech SE · 1 shared drug class
  7. Coherus Oncology, Inc. · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Genmab:

Cite this brief

Drug Landscape (2026). Genmab — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genmab. Accessed 2026-05-14.

Related